"Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep And High Responses In The Treatment Of Relapsed Or Refractory Multiple Myeloma"
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. "These initial results from the Phase 1b portion of the CARTITUDE-1 study highlight a compelling clinical profile for JNJ-4528 in heavily pre-treated patients with relapsed or refractory multiple myeloma," said principal investigator Deepu Madduri, MD, assistant professor of medicine, hematology, urology and medical oncology, Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
— Deepu Madduri, MD, Assistant Professor, Medicine, Hematology, Medical Oncology, Urology, Assistant Director, Cellular Therapy Service, Multiple Myeloma at The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Additional coverage: Onclive;Medscape;Oncology Times; Cure Today;OBR Oncology; MedPage Today; Healio: HemOnc Today;Onco'Zine; Pharma Times